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Environmental factors contribute to the initiation, progression, and maintenance of type 
1 diabetes (T1D), although a single environmental trigger for disease has not been iden-
tified. Studies have documented the contribution of immunity within the gastrointestinal 
tract (GI) to the expression of autoimmunity at distal sites. Intestinal epithelial cells (IECs) 
regulate local and systemic immunologic homeostasis through physical and biochemical 
interactions with innate and adaptive immune populations. We hypothesize that a loss in 
the tolerance-inducing nature of the GI tract occurs within T1D and is due to altered IECs’ 
innate immune function. As a first step in addressing this hypothesis, we contrasted the 
global immune microenvironment within the GI tract of individuals with T1D as well as 
evaluated the IEC-specific effects on adaptive immune cell phenotypes. The soluble and 
cellular immune microenvironment within the duodenum, the soluble mediator profile of 
primary IECs derived from the same duodenal tissues, and the effect of the primary IECs’ 
soluble mediator profile on T-cell expansion and polarization were evaluated. Higher lev-
els of IL-17C and beta-defensin 2 (BD-2) mRNA in the T1D-duodenum were observed. 
Higher frequencies of type 1 innate lymphoid cells (ILC1) and CD8+CXCR3+ T-cells 
(Tc1) were also observed in T1D-duodenal tissues, concomitant with lower frequencies 
of type 3 ILC (ILC3) and CD8+CCR6+ T-cells (Tc17). Higher levels of proinflammatory 
mediators (IL-17C and BD-2) in the absence of similar changes in mediators associated 
with homeostasis (interleukin 10 and thymic stromal lymphopoietin) were also observed 
in T1D-derived primary IEC cultures. T1D-derived IEC culture supernatants induced more 
robust CD8+ T-cell proliferation along with enhanced polarization of Tc1 populations, 
at the expense of Tc17 polarization, as well as the expansion of CXCR3+CCR6+/− 
Tregs, indicative of a Th1-like and less regulatory phenotype. These data demonstrate 
a proinflammatory microenvironment of the T1D-duodenum, whereby IECs have the 
potential to contribute to the expansion and polarization of innate and adaptive immune 
cells. Although these data do not discern whether these observations are not simply 
a consequence of T1D, the data indicate that the T1D-GI tract has the capacity to 
foster a permissive environment under which autoreactive T-cells could be expanded 
and polarized.
Keywords: type 1 diabetes, mucosal immunity, intestinal epithelium, primary iec, adaptive immunity, T cell 
proliferation, T cell polarization
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inTrODUcTiOn
Type 1 diabetes (T1D) is a polygenic disease resulting from the 
triad of β-cell fragility, failure to regulate innate immunity, and 
failure to regulate adaptive immunity (1–3). To complicate mat-
ters, it is appreciated that environmental factors contribute to 
the initiation and progression of T1D, yet a single environmental 
trigger has not been identified (4). Thus, we propose that rather 
than solely the identity of the trigger, the nature of the host 
responses to environmental triggers is also contributing to the 
etiology of T1D. Integral to the sensing of the environment is the 
gastrointestinal tract (GI), which is the largest environmental 
interface in the human body (5). In health, the GI tract acts 
not only as a gatekeeper allowing absorption of nutrients and 
limiting passage of dietary, bacterial, and viral antigens but 
also contributes to the maintenance of immune tolerance (6). 
Previous studies have demonstrated that diet, changes in com-
mensal microbiota, and alterations in intestinal permeability can 
all modulate autoimmune diabetes in animal models (7, 8). In 
addition, studies in humans have found associations between 
subclinical intestinal immune activation with T1D, as measured 
by local cytokine expression and frequency of both regulatory 
(Tregs) and inflammatory (Th17 cells) immune cells (7, 8). 
While these data implicate alterations in GI-sensing of the envi-
ronment in individuals with T1D, the associated mechanisms 
leading to the observed immune microenvironment are yet to 
be described.
For instance, innate lymphoid cells (ILC), a recently 
described class of innate immune cells critical in maintenance 
and regulation of mucosal homeostasis through modulation of 
both innate and adaptive immunity, have not been evaluated in 
T1D (9–12). Similarly, it has been demonstrated that intestinal 
epithelial cells (IECs) upregulate innate immune functions at 
the expense of nutrient absorption indicating a dichotomous 
state where under conditions of immune dysregulation IEC may 
function primarily as innate immune effector cells. Here, IECs 
can biochemically regulate innate and adaptive immune cell 
populations (13, 14), yet IEC-innate immune function has also 
not been evaluated in T1D. This is in part due to the inacces-
sibility of sufficient and appropriate GI tissues from individuals 
with and without T1D. In collaboration with the Network for 
Pancreatic Organ Donors (nPOD), we have established methods 
to not only isolate and characterize immune cell populations 
within human duodenal tissues but to also establish primary 
IEC cultures from the same tissues (15). Thus, in order expand 
on the existing knowledge associated with the GI-immune 
microenvironment observed in T1D, we evaluated the soluble 
mediator milieu as well as the frequency and phenotype of ILC, 
T helper cells (CD4+), and cytotoxic T-cells (CD8+) within 
duodenal tissues in a cohort of organ donors with and without 
T1D. In order to begin to delineate mechanisms contributing 
to the observed GI-immune microenvironment, the resting 
IEC-innate immune profile of primary IECs derived from 
the same duodenal tissues was evaluated, and the effect of the 
innate immune profile on adaptive immune cell expansion and 
polarization was characterized.
MaTerials anD MeThODs
Participant cohort and study Design
Fresh duodenal tissue was obtained from the nPOD (Gainesville, 
FL, USA). All experiments were performed according to the 
guidelines of the University of Florida Institutional Review 
Board, with written informed consent from all subjects. All 
subjects gave written informed consent in accordance with 
the Declaration of Helsinki. The protocol was approved by 
University of Florida Institutional Review Board. Included in 
the current study were 17 T1D and 13 non-T1D cases (Table 
S1 in Supplementary Material). When the proximal duodenum 
is included with pancreases donations, the duodenal tissue is 
harvested following the isolation of pancreatic tissues, pancre-
atic lymph nodes, spleen, and non-pancreatic lymph nodes. 
Specifically, the duodenum is opened and the mucosa cleaned 
of mucous and bacterial content with a moistened gauze pad 
after which a section is placed in transport media and imme-
diately processed as follows. While the all organs are harvested 
according to the same protocol in every case, the time from 
death to organ harvest and thus confounders such as ischemia 
are not available. For each case, 8.0  g of duodenal tissue was 
processed as follows: (1) 0.3 g of tissue was preserved for (1a) 
protein extraction and (1b) RNA extraction to evaluate the 
soluble mediator profile of the duodenum by ELISA and real-
time PCR, respectively. (2) The remaining tissue was processed 
for (2a) intestinal immune cell isolation and (2b) intestinal 
crypt isolation for characterization of resident immune cell 
population by flow cytometry and establishment of primary 
IEC cultures, respectively (15). (3) Following the establishment 
of confluent primary IEC cultures (3a) culture supernatants 
and (3b) cellular mRNA were collected to evaluate the soluble 
mediator profile of the primary cultures by ELISA and real-time 
PCR, respectively. (4) In order to evaluate the effect of the T1D 
and non-T1D-derived IEC-soluble mediator profile on T cell 
proliferation and polarization, T cells were isolated from a single 
systemically healthy individual (not part of the experimental 
cohort) and activated in the presence of supernatants from rest-
ing IEC cultures described in step 3, after which the subsequent 
T cell proliferation and polarization was characterized by flow 
cytometry. Please note while all samples (n = 17 T1D and n = 13 
non-T1D) underwent evaluation for experiments outlined step 
1, due to timing of receipt, only a subset of these samples (n = 8 
and n = 10) underwent evaluation for experiments outlined in 
steps 1–4 (Table 1; Table S1 in Supplementary Material).
Whole Tissue Protein and mrna 
extraction
A total of 0.3 g of duodenal tissue was minced and homogenized 
by bead beating in cell extraction buffer (Life Technologies, 
Carlsbad, CA, USA) prepared with a protease inhibitor cocktail 
(cOmplete, Roche, Basel, Switzerland) and PMSF protease inhibi-
tor (Life Technologies). Protein samples were stored at −80°C 
until ELISA could be performed. An additional 0.3 g of duodenal 
tissue was minced and homogenized by bead beating in Buffer 
Table 1 | cohort demographics.
group 1 Type 1 diabetes (TiD) (n = 17) non-T1D (n = 13)
Age (±SEM) 30.8 (±3.28) 23.9 (±5.02)
Duration (±SEM) 16.8 (±3.24) n/a
Sex (M/F) 12/5 10/3
Group 2 T1D (n = 8) Non-T1D (n = 10)
Age (±SEM) 34.3 (±5.77) 26.6 (±6.30)
Duration (±SEM) 19.13 (±6.40) n/a
Sex (M/F) 6/2 7/3
Cases in Group 1 underwent analysis to evaluate the soluble mediator profile of the 
duodenum by ELISA and real-time PCR. Cases in Group 2 are a subset of those in 
Group 1 that also were subjected to analysis for resident immune cell population by 
flow cytometry and establishment of primary intestinal epithelial cell (IEC) cultures and 
the effect of IEC-soluble mediator profile on T cell proliferation and polarization. Please 
note, there are no statistical differences in the age, duration, and/or sex distribution 
between groups and/or disease diagnosis.
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RLT (Qiagen, Hilden, Germany) containing β-mercaptoethanol 
(β-ME) and total RNA harvested using an RNeasy extraction 
kit (Qiagen, Hilden, Germany) and also stored at −80°C until 
quantitative PCR (RT-qPCR) could be performed.
intestinal crypt and immune cell isolation
Crypts and resident immune cells were liberated using a protocol 
adapted from Booth and O’Shea (15–17). Human duodenal tis-
sues were prepared by removing the longitudinal muscle layer and 
washing with ice-cold Mg2+- and Ca2+-free Hank’s Balanced Salt 
Solution (HBSS) (Mediatech, Manassas, VA, USA) containing 
100 U penicillin, 100 μg/mL streptomycin (Mediatech), 25 μg/
mL gentamycin (MP Biomedicals, Solon, OH, USA), and 0.5 mM 
dithiothreitol (DTT) (Thermo Fisher Scientific). After which the 
tissue was cut to yield 2 cm2 pieces, suspended in 50 mL of HBSS 
wash solution, inverted vigorously 10 times, and the contents 
allowed to settle for 1  min. The supernatant was removed and 
the process repeated four times. After the fifth wash, the settled 
contents were removed, minced with a sterile surgical scalpel, and 
suspended in 50  mL of the HBSS wash solution. The resulting 
solution was passed over a 400 μm2 filter, and the flow-through 
was collected for resident immune cells analysis (data not shown). 
The remaining tissue was digested in 50 mL of a buffer contain-
ing 75 U/mL collagenase type XI (Sigma-Aldrich, St. Louis, MO, 
USA), 20 μg/mL dispase neutral protease II (Roche, Indianapolis, 
IN, USA), 0.5 mM DTT, and 1% v/v fetal bovine serum (FBS) 
(Thermo Fisher Scientific) in Dubelcco’s Modification of Eagles 
Medium with 4.5 g/L glucose and l-glutamine, without sodium 
pyruvate (DMEM) (Corning, Corning, NY, USA). The digestion 
buffer containing the tissue was then evenly divided, placed in 
a 37°C incubator, and allowed to shake at 180 RPM for 3 h. The 
resulting digestion mixture was again passed over a 400  μm2 
filter, and the tissue fragments atop the filter were washed with 
25 mL complete growth media {DMEM [8.5 g/L sodium pyruvate 
(Mediatech)], 2.5% v/v FBS, 0.25 U/mL insulin (Sigma-Aldrich), 
100 U penicillin, 100 μg/mL streptomycin, 25 μg/mL gentamycin, 
5 μg/mL transferrin (Sigma-Aldrich), and 10  ng/ml epidermal 
growth factor (Sigma-Aldrich) containing 2% w/v d-sorbitol 
(Sigma-Aldrich)}. The tissue debris remaining in the filter was 
discarded, and the flow-through containing proliferative crypt 
structures and liberated intestinal immune cells was centrifuged 
at 200 × g for 4 min. The resulting pellet of intestinal crypts was 
used for the establishment of IEC cultures as described below. 
The resulting supernatant was collected for resident immune 
cells, which were cryopreserved at 1  ×  106 cells/mL in cell 
freezing media (ScienCell Research Laboratories, Carlsbad, CA, 
USA) and stored in liquid nitrogen until flow cytometry could 
be performed.
iec culture and stimulation
Intestinal epithelial cell cultures were established from isolated 
crypts as previously described (15, 17) and maintained in 24-well 
collagen-coated culture dishes (Greiner Bio-One, Monroe, NC, 
USA) in 1 mL complete IEC (cIEC) media [DMEM, 5 g/L sodium 
pyruvate (Mediatech), 2.5% v/v FBS, 0.25 U/mL insulin (Sigma-
Aldrich), 100 U penicillin, 100 µg/mL streptomycin, 25 µg/mL 
gentamicin, 5  µg/mL transferrin (Sigma-Aldrich), 10  ng/mL 
epidermal growth factor (Sigma-Aldrich)]. Cultures were left 
unstimulated for 24 h after which supernatants were collected and 
stored at −80°C. In addition, cellular total RNA was harvested 
using an RNeasy extraction kit (Qiagen, Hilden, Germany) and 
stored at −80°C until RT-qPCR could be performed.
soluble Mediator analysis
Reverse transcription and RT-qPCR was performed according 
to MIQE guidelines (18). Synthesis of cDNA was performed 
using SuperScript® Reverse Transcriptase (Life Technologies), 
whereby RT-qPCR was performed using primer sets (Table S2 
in Supplementary Material), and SsoAdvanced™ SYBR Green 
Supermix was used according to manufacturer recommenda-
tions. Data were collected and analyzed using CFX Connect™ 
and CFX Manager™ (Bio-Rad Laboratories, Berkeley, CA, USA) 
according to the ddCT algorithm using 18S as a reference gene 
and are presented as fold change. ELISA technology (EMD 
Millipore, Billerica, MA, USA) was used according to manufac-
turer protocol to assess whole tissue and primary IEC production 
of interleukin 10 (IL-10). Data were analyzed using a standard 
curve, positive, and negative control. For whole tissue expres-
sion, all data were normalized to total protein, while media-only 
levels were subtracted from primary IEC expression, which was 
normalized to 18S RNA levels from each primary cell culture.
Flow cytometry
Cryopreserved intestinal immune cells were thawed from 
liquid nitrogen at 37°C, washed, and suspended in PBS prior to 
incubation with a fixable Live/Dead Yellow viability dye (Life 
Technologies) for 10  min at RT. Following Fc receptor block-
ing (Human TruStain FcX™, BioLegend), surface staining was 
performed in FACS buffer [PBS, 1% FBS, 4  mM EDTA, and 
antibiotics (penicillin, streptomycin, and amphotericin B)] 
interrogating expression of lineage markers (CD3, CD14, CD19, 
CD20), CD56, CD127, CD117, NKp44, CD45, CD3, αβ TCR, 
γδ TCR, CD4, CD8, CCR6, CXCR3 (Table S3 in Supplementary 
Material). Intracellular staining for FOXP3 and HELIOS was 
performed using FOXP3 Fix/Perm Buffer Set (BioLegend). All 
antibodies were used at manufacturer-recommended concentra-
tions. Fluorescence minus one or isotype controls were used 
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as indicated. Data were acquired using a BD LSR Fortessa (BD 
Biosciences, Franklin Lakes, NJ, USA) cytometer and analyzed 
using FlowJo data analysis software (FlowJo, LLC, Ashland, OR, 
USA). All data were normalized to 1,000,000 total cells collected 
in the lymphocyte gate and are presented as frequencies and total 
cell numbers.
Proliferation assays
Peripheral blood mononuclear cells (PBMC) were isolated from 
the buffy coat of a single healthy donor (not part of the experi-
mental cohort) by centrifugation (400 × g, 30 min, no brake) on 
Ficoll-Paque Premium (GE Healthcare Life Sciences, Pittsburgh, 
PA, USA). Cells were washed twice with HBSS and plated at a 
density of 1 × 106 cells/mL with either 50% cRMPI/50% cIEC, 
or 50% cRPMI/50% 24-h supernatants from T1D- or non-T1D-
derived IEC cultures. T cells were activated with Dynabeads® 
Human T-Activator CD3/CD28 (Life Technologies) at a 1:1 
bead to cell ratio with IL-2 (100 U/mL) for 4 days. CellTrace™ 
Violet-cell proliferation kit (Life Technologies) was used accord-
ing to manufacturer protocols to evaluate CD3+ proliferation. 
Proliferation index was defined as the average number of divi-
sions of each T cell as calculated by 1/sum[pn/(2n)].
histopathological assessment
Hematoxylin- and eosin-stained sections of duodenum from 
all cases were obtained from nPOD and blindly evaluated by 
an experienced histopathologist (Jian Li) according to Marsh–
Oberhuber classification (19) (Table S4 in Supplementary 
Material). Additional 5 µm sectioned slides of duodenum from 
all cases were used to assess goblet cell frequency by Periodic-acid 
Schiff staining (Sigma-Aldrich, St. Louis, MO, USA) according 
to the manufacturer protocol. Additional 5-µm tissue sections of 
duodenum from all cases were used to assess expression of HLA 
class II. Specifically, sections were deparaffinized and rehydrated 
prior to antigen retrieval in a sodium citrate buffer (10  mM 
sodium citrate, 0.05% Tween-20, pH 6.0; 96.5°C, 20 min). Slides 
were rinsed with PBS and permeabilized in a blocking buffer [1% 
(w/v) BSA, 10% (v/v) donkey serum, 0.1% (v/v) Triton X-100 
in PBS]. Primary antibodies were used to probe for HLA-DR 
(TAL.1B5, Dako, Carpinteria, CA, USA) (16 h, 4°C, 1:20 in block-
ing buffer). Following three washes in PBS containing 3% (w/v) 
BSA and 0.1% (v/v) Triton X-100, tissue sections were probed 
with donkey anti-mouse AlexaFluor® 488 (Life Technologies) 
(3 h RT, 1:400 in PBS). Following three washes in PBS, sections 
were mounted with VECTASHIELD® HardSet Antifade (Vector 
Laboratories, Burlingame, CA, USA). Images were acquired with 
an EVOS® FL (Life Technologies) and analyzed and quantified 
using ImageJ software (20). Data are presented as the mean 
fluorescence intensity difference of the region of interest and 
background. Exposure time and brightness and contrast adjust-
ments were applied identically across all groups. A rainbow LUT 
was applied for visualization.
statistical analyses
Data are expressed as mean  ±  SEM unless otherwise noted. 
Differences between groups were analyzed by the one-tailed 
Mann–Whitney t test using GraphPad Prism 6 software 
(GraphPad Software, San Diego, CA, USA). Differences in fold 
change of expression were analyzed by Wilcoxon matched-pairs 
signed rank test. Results were considered statistically significant 
at p ≤ 0.05.
resUlTs
T1D-associated intestinal innate  
immune activation
Previous studies using small intestinal biopsy samples from 
relatively small cohorts of children with T1D have suggested 
intestinal immune activation in some individuals with T1D (7, 
8). In order to determine if this altered intestinal microenvi-
ronment in TID extended to that of the IEC-specific compart-
ment, the expression of various IEC-specific soluble mediators 
associated with immunoregulation and inflammation and were 
assessed in duodenal tissues from donors with or without T1D 
(Table 1).
In duodenal tissues derived from individuals with T1D, a 
21-fold higher level of mRNA expression of the antimicrobial 
peptide beta-defensin 2 (BD-2) and a 61-fold higher level of 
mRNA expression of IL-17C were observed (Figures  1A,B). 
Importantly, these mediators were significantly elevated in the 
absence of similar mRNA elevations in the regulatory cytokines 
thymic stromal lymphopoietin (TSLP) and protein expression 
of IL-10 (Figures 1A–C). As BD-2 and IL-17C are known to be 
TLR5-response genes (21, 22), expression levels of TLR5 were 
also evaluated, whereby no significant differences in the mRNA 
levels of TLR5 were observed (Figures 1A,B).
The inflammatory state of the intestinal tract is heavily 
regulated by and has a direct effect on the recently described ILC 
lineage (9). Thus, the frequency and phenotype of ILC within the 
duodenal tissues were also evaluated. Although no significant 
differences were observed in the frequency of total NK or ILC 
populations (Figures  2A,B), a significantly higher frequency 
of CD127+NKp44−CD117− cells (ILC1) concomitant with a 
lower frequency of CD127+CD117+NKp44+/− cells (ILC3) was 
observed in the T1D cohort compared to that of the non-T1D 
cohort (Figures 2C–E).
T1D-associated intestinal adaptive 
immune activation
Immune cell plasticity within the adaptive immune cell compart-
ments is also heavily regulated by the inflammatory state of the 
intestinal tract, thus the frequency and phenotype of T helper 
cells (CD4+) and cytotoxic T-cells (CD8+), within the duodenal 
tissues, were also evaluated (23). Similar to that of the total ILC 
populations, no significant difference in the frequencies of total 
CD3+, αβ+ nor γδ+ T-cells were observed between the TID 
and non-TID cohorts (Figures 3A–C). Furthermore, within the 
αβ+ T-cell populations, similar frequencies of CD4+ and CD8+ 
T-cells were observed (Figures 3A,B). Surprisingly, no significant 
differences in the frequency of duodenal CD4+CXCR3+ (Th1), 
CD4+CCR6+ (Th17) or CD4+CXCR3+CCR6+ (Th1/Th17), or 
CD4+FOXP3+ T-cells (Tregs) was observed (Figures 3A,C,E–G). 
Conversely, mirroring the observed phenotypic skewing of ILCs, 
FigUre 2 | Type 1 diabetes (T1D) is associated with duodenal accumulation of type 1 innate lymphoid cells (ilc1). (a) Intestinal ILCs gating strategy. 
(b) Frequency of and total cell numbers for intestinal NK cells (lineage negative, CD56+, CD127−) and ILC (lineage negative, CD127+). (c) Intestinal ILCs subset 
gating strategy (CD117−NKp44− Tbet+; CD117+NKp44+/−, RORγT+) (D) Tbet—blue histogram (Tbet high cells) is gated on CD117−NKp44−; red histogram 
(Tbet low cells) is gated on CD117+NKp44+/−; RORγT—blue histogram (RORγT high cells) is gated CD117+NKp44+/−; red histogram (RORγT low cells) is gated 
on CD117−NKp44−. (e) Frequency of and total cell numbers for intestinal ILC1 (CD127+CD117−NKp44−Tbet+) and ILC3 (CD117+NKp44+/−RORγT+). Gray 
bars: T1D (n = 8); white bars: non-T1D (n = 10). *p ≤ 0.05.
FigUre 1 | Type 1 diabetes (T1D) is associated with elevated levels of beta-defensin 2 and il-17c within duodenal lysates. (a) Delta CT value [gene of 
interest (GOI)—18S] of each gene evaluated in duodenal lysates from individuals with and without T1D. Please note the higher value indicates lower expression of 
the GOI. (b) Fold change of mRNA expression of indicated genes in duodenal lysates from individuals with T1D over mRNA expression in duodenal lysates from 
individuals without T1D. (c) Protein expression of interleukin 10. Gray bars: T1D (n = 17); white bars: non-T1D (n = 13). **p ≤ 0.01.
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the T1D cohort presented with a significantly higher frequency 
of duodenal CD8+CXCR3+ (Tc1) T-cells as well as a significantly 
lower frequency of CD8+CCR6+ (Tc17) T-cells (Figures 3A,D), 
although the frequency of CD8+CXCR3+CCR6+ (Tc1/Tc17) 
was similar between the cohorts (Figures 3A,E) (24, 25).
T1D-associated iecs Mediate Polarization 
of adaptive immunity
Appropriate communication of the intestinal tract with the 
environment is required for local and systemic immunologic 
homeostasis, which is in part regulated by the IEC through its 
physical and biochemical interactions with innate and adaptive 
immune populations (13). Thus, to determine if the phenomenon 
observed at the whole tissue level could be a result of altered 
IEC-innate immune function, primary IEC cultures were estab-
lished from the crypts of duodenal tissues using our previously 
published method (15) (Table S1 in Supplementary Material). 
Here, the soluble mediator gene expression profile of resting T1D-
derived IEC cultures was similar to that observed in the whole 
tissue, whereby 5- and 3.6-fold higher mRNA levels of BD-2 and 
IL-17C, respectively, were observed in T1D-derived cultures, 
when compared to non-TID derived cultures (Figures  4A,B), 
without similar upregulation in immunoregulatory mediators 
such as TSLP or IL-10 (Figures 4A–C). Again, this altered soluble 
mediator expression was in the absence of significant differences 
in the mRNA levels of TLR5 (Figures 4A,B).
To determine if the T1D-associated IEC-soluble mediator 
milieu could directly contribute to expansion and/or polariza-
tion of the T-cell compartment observed at the whole tissue 
FigUre 4 | innate immune dysregulation is a feature of the type 1 diabetes (T1D)-derived intestinal epithelial cell (iec). (a) Delta CT value [gene of 
interest (GOI)—18S] of each gene evaluated in unstimulated IEC cultures from individuals with and without T1D. Please note a higher value indicates lower 
expression of the GOI. (b) Fold change of mRNA expression of indicated genes in unstimulated IEC cultures from individuals with T1D over mRNA expression in 
unstimulated IEC cultures from individuals without T1D. (c) Unstimulated protein expression of interleukin 10. (a,b) Gray bars: T1D (n = 8); white bars: non-T1D 
cohort (n = 10).
FigUre 3 | Type 1 diabetes (T1D) is associated with elevated inflammatory duodenal cD8+ effector T-cell populations. (a) Intestinal T lymphocyte 
gating strategy. (b) Frequency of and total cell numbers for CD3+ T-cells, α/β or γ/δ T-cells, and CD4+ or CD8+ T-cells. (c–e) Frequencies of and total cell numbers 
for (c) CD4+ or CD8+CXCR3+, (D) CD4+ or CD8+CCR6+, and (e) CD4+ or CD8+CXCR3+CCR6+ T-cells. (F) CD4+FOXP3+ T-cell gating strategies.  
(g) Frequency of and total cell numbers for CD4+FOXP3+ Tregs. Gray bars: T1D (n = 8); white bars: non-T1D (n = 10). *p ≤ 0.05, **p ≤ 0.01.
6
Graves et al. Intestinal Dysfunction in Autoimmune Diabetes
Frontiers in Immunology | www.frontiersin.org January 2017 | Volume 7 | Article 679
level, the proliferative capacity and polarization of PBMC from 
a single healthy donor was assessed following exposure to 
IEC-conditioned supernatants. Here, the proliferation of CD3+ 
T-cells was significantly enhanced when exposed to conditioned 
supernatants from T1D-derived IEC cultures, mostly as a result 
of CD8+ T-cell expansion (Figures 5A,B). While conditioned 
supernatants from T1D-derived IEC cultures induced a similar 
polarization profile of CD4+ T-cell subsets, as did conditioned 
supernatants from non-T1D-derived IEC cultures (Figure 5D), 
there was a statistically significant difference in the effects on 
the CD8+ T-cell populations (Figures  5C,E). Specifically, 
the frequency of CD8+CXCR3+CCR6+/− T-cells (Tc1) 
was higher following exposure to conditioned supernatants 
from T1D-derived cultures, whereby the expression level of 
CXCR3+ was also significantly elevated on a per cell basis 
(Figures  5C,E). Similarly, while both sources of conditioned 
supernatants induced an expansion of CD4+FOXP3+ T-cells 
(Tregs) (Figure  5F), supernatants from T1D-derived IEC 
FigUre 5 | Type 1 diabetes (T1D)-derived intestinal epithelial cell (iec) conditioned media induce inflammatory cD8+ effector T-cell proliferation and 
polarization. (a) Representative peripheral blood mononuclear cells proliferation data gated on CD3+ T cells following coculture with T1D- and non-T1D-derived 
IEC culture supernatants. (b) CD3+, CD4+, and CD8+ expansion index. (c) Representative CD4+ and CD8+ T cell gating strategy and histograms for relative 
levels of CXCR3+ cells red: using conditioned media from T1D IEC cultures; blue: using conditioned media from non-T1D IEC cultures. (D,e) Frequency and 
expression levels of CXCR3−CCR6+ and CXCR3+CCR6+/− among (D) CD4+ and (e) CD8+ T-cell populations. (e) Frequency of FOXP3+ Tregs. (F) Frequency 
and expression levels of CXCR3−CCR6+ and CXCR3+CCR6+/− among FOXP3+ Tregs. Gray bars: conditioned media from T1D IEC cultures (n = 8); white bars: 
conditioned media from non-T1D IEC cultures (n = 10); hatched bars: media alone (n = 10). *p ≤ 0.05, **p ≤ 0.01.
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cultures polarized Tregs to that of a more Th1-like phenotype 
as measured by a higher frequency of CD4+FOXP3+CXCR3+
CCR6+/− T cells (Figure 5F).
T1D-associated iec activation Occurs in 
the absence of Overt intestinal Pathology
As previous studies had indicated intestinal inflammation 
inherent in T1D cohorts, the duodenal samples of this cohort 
were also evaluated for overt intestinal pathology and markers 
of intestinal inflammation. Specifically, all tissues were evaluated 
for gross pathology, goblet cell and intraepithelial lymphocyte 
(IEL) frequency, and expression of HLA-DR. Interestingly, the 
absence and presence of intestinal pathology were observed in 
both cohorts with similar incidence (Figure  6A), whereby no 
statistical differences in the frequency of goblet cells (Figure 6B), 
IELs (Figure  6C), or HLA-DR expression (Figure  6D) was 
observed.
FigUre 6 | Type 1 diabetes (T1D)-associated intestinal epithelial cell (iec) activation occurs in the absence of overt intestinal pathology. (a) Mild and 
severe intestinal pathology in both T1D and non-T1D cohorts. (b) Goblet cell frequency. (c) Histological analysis of intraepithelial lymphocyte frequency. 
(D) Immunofluorescence of epithelial HLA-DR expression. Arrows indicate IEC HLA expression and asterisks indicate lamina propria immune cell HLA expression. 
Gray bars: T1D (n = 17); white bars: non-T1D (n = 13).
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DiscUssiOn
Non-genetic factors account for greater than 60–70% of the 
immunological variations between individuals, whereby a 
recent study demonstrated that the two major non-genetic 
factors contributing to immunological distance between 
individuals are age and cohabitation (26). These data suggest a 
shared environment acts in some way to bring immunoprofiles 
toward a convergent equilibrium (26). T1D is an autoimmune 
disease, whereby genetics contribute to the immunoprofiles 
responsible for the destruction of β-cells and loss of insulin 
production. Similar to those observations in health, it is long 
accepted that genetic susceptibility is not sufficient for T1D to 
manifest and only upon exposure to environmentally acquired 
factors is full-blown autoimmunity realized (7). More impor-
tantly, data emerging from preclinical and immunotherapy 
trials in T1D suggest that interfaces with the environment 
contribute to not only the induction of immune regulation but 
also to the reinforcement of pathological immune responses, 
although the associated mechanisms have yet to be elucidated 
(27, 28).
The largest environmental interface in the human body is 
the GI tract, a highly regulated immunological organ, which is 
in part responsible for the maintenance of peripheral tolerance 
under conditions of health. The sentinel cell of the GI tract 
responsible for environmental sensing is the IEC, whereby IECs 
have the capacity to regulate innate and adaptive immune popu-
lations (13). In addition, a number of studies have documented 
the contribution of immunity within GI tract to the expression of 
autoimmunity at distal sites, but it is unclear how the responses 
observed translate to antigen-specific immunity in the target 
tissue (29–31). Prior studies using animal models of disease and 
data generated from human intestinal biopsies have suggested 
that the intestine may either be involved in the pathogenesis 
of T1D or at a minimum be affected by the pathogenesis of 
disease (7, 8). Here, we have comprehensively characterized the 
duodenal IEC-specific immunological microenvironment in 
the human condition of T1D. Data presented here support the 
findings that innate and adaptive immune microenvironment of 
the T1D-GI tract is indeed altered at least following the onset of 
clinical disease. Importantly, our data suggest that this altered 
immune microenvironment is not solely due to histopathologi-
cal changes of the GI tract, but more likely is at least partially 
dependent on the function of the IEC. In addition, within the 
T1D cohort, there was no correlation between sex, age, and/or 
duration of disease with any of the immunological parameters 
evaluated (data not show), again suggesting that the phenom-
enon observed may be a significant component of the etiology of 
disease. While it is clear that the soluble mediator profile of the 
IEC is directly contributing to the immune microenvironment 
at the whole tissue level and the expansion and polarization of T 
cell populations, we have not evaluated the totality of the soluble 
mediator environment at the whole tissue or IEC-specific level. 
For instance, retinoic acid-dependent production of TSLP and 
IL-22 in γδ T-cells, ILC3, and non-immune cells has been impli-
cated in the maintenance of mucosal homeostasis, and we have 
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yet to evaluate whether this axis is disrupted in T1D (32, 33). 
Studies to more fully elucidate the soluble mediator environment 
under conditions of health as well as T1D will be critical to the 
design and implementation of adjunctive therapies needed to 
induce proper mucosal tolerance.
The ideal therapy for T1D is one which would restore 
immune balance in a safe and lasting fashion (28). Both 
antigen-specific and non-specific tolerance-inducing thera-
pies for T1D have been evaluated in preclinical models, which 
have not been successful in translating to the clinic due to the 
fact they were unable to confirm preclinical observations (27, 
28). The reasons for this include (but are not limited to) differ-
ences in murine and human immune responses as well as lack 
of access to tissue compartments where important immune 
response may be occurring in patients (27, 34, 35). Indeed, a 
recent study using humanized mouse models indicated that 
anti-CD3 therapeutic efficacy is through a novel mechanism 
where human GI-tropic T-cells leave the circulation and sec-
ondary lymph organs and migrate to the small intestine and 
become producers of IL-10 (27). Most importantly, blockade 
of T-cell migration to the small intestine abolishes the treat-
ment effects (27). These data highlight the potential role of 
the GI tract in secondary priming of effector T-cells, the small 
intestine as a potential reservoir of autoreactive T-cells, and/
or differences in mechanisms of mucosal tolerance in the 
human condition. Intestinal inflammation can contribute to 
a loss of tolerance through changes in ILC, DC, and T-cell 
phenotypes and functions (10, 36–38). With the emergence 
of better technical approaches to track the fate of defined 
immune cell populations it has become apparent that there 
is substantial plasticity in ILC, T effector, and Treg subsets 
(39–41), whereby this plasticity is observed in both mice and 
humans (42). Indeed, our data demonstrate that phenotypic 
plasticity among GI tract-resident ILC and T-cell populations 
occurs in human T1D, lending to a more proinflammatory 
microenvironment with the T1D-duodenum. In addition, 
data presented here demonstrate the capacity of IEC to not 
only expand effector T cell populations but also to shape their 
phenotype and thus function. Importantly, we demonstrate 
that IECs from individuals with T1D preferentially expand and 
polarize T cells with pathogenic potential, and finally, that this 
can occur in the human condition. Future studies will address 
the effect of T1D-associated altered IEC function on ILC or 
DC phenotypes and functions.
It is becoming increasingly clear that cooperation among the 
intestinal microbiota, the intestinal barrier, and the mucosal 
immune system are pivotal to mucosal health and are often per-
turbed in T1D (43). Indeed, previous studies have demonstrated 
that alterations in the commensal microbiota are associated 
with human disease, and modulation of the microbiota can 
modulate disease incidence in animal models (44). As such, one 
limitation of our study is that we did not evaluate the microbiota 
associated with these duodenal tissues and thus cannot eliminate 
the contribution of its composition on the soluble and cellular 
immunoprofiles observed. However, though the microbiome 
directly and indirectly affects mucosal homeostasis, it is still 
unclear as to whether changes in the microbiome precede immu-
nological alterations and loss of mucosal tolerance or are rather 
a reflection of an altered mucosal environment. Our data would 
suggest that altered innate sensing of IECs in T1D could have an 
impact on the composition of the microbiota; as such, under-
standing microbiota–IEC interactions in T1D represents an area 
of future study. An additional limitation of our study is that all 
data were gathered using tissues from cadaveric donors and thus 
represent data from different time points following diagnosis 
and clinical onset of disease. Therefore, our data are unable to 
address whether the phenomena described arise as a cause or 
consequence of disease. With that said, these data can be used 
to better inform the design, implementation, and evaluation of 
interventions, which are most commonly administered at these 
later stages of disease. Specifically, our data lend some insight 
into why vaccinations and attempts at establishment of mucosal 
tolerance in human T1D trials have been largely unsuccessful; 
specifically, an underlying defect in the ability to establish toler-
ance due to either robust mucosal inflammation and/or altered 
IEC-innate immune function (45).
In summary, these studies demonstrate that the perturbed 
innate immune function of IECs, which serve as a first line 
of communication with the environment, might foster a 
permissive environment under which autoreactive T-cells 
can be expanded and polarized. Thus, we propose that while 
IEC-innate immune dysfunction may be an early initiating 
event of pathogenesis, sustained IEC-driven intestinal immune 
dysfunction may also explain the failure of therapies aimed at 
establishing oral tolerance to β-cell antigens. Addressing or 
correcting these alterations in intestinal innate immune func-
tion may create an intestinal immune environment conducive 
to therapeutic intervention and thus aid efforts to establish oral 
tolerance.
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